TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Task Shifting and Blood Pressure Control in Ghana: A Cluster-Randomized Trial
Brief Summary: The goal of this study is to evaluate the comparative effectiveness of the World Health Organization Package targeted at Cardiovascular (CV) risk assessment and hypertension control, delivered by Community Health Nurses as part of Ghana's Community based Health Planning and Services program, versus provision of health insurance coverage, on blood pressure reduction. Findings from this study will provide policy makers and other stakeholders needed information to recommend efficient cost-effective policy with regards to comprehensive CV risk reduction in patients with hypertension in low resource settings.


Options:
A: Arm Label: Updated CHD risk profiles; Type: EXPERIMENTAL; Interventions: Behavioral: Updated CHD risk profiles | Arm Label: Guidelines; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Guidelines | Intervention Type: BEHAVIORAL; Name: Updated CHD risk profiles; Assigned to Arm(s): Updated CHD risk profiles | Intervention Type: BEHAVIORAL; Name: Guidelines; Assigned to Arm(s): Guidelines
B: Arm Label: WHO CVD Risk Assessment package; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WHO CVD risk assessment package | Arm Label: Health Insurance only; Type: SHAM_COMPARATOR; Interventions: Behavioral: Health Insurance only | Intervention Type: BEHAVIORAL; Name: WHO CVD risk assessment package; Assigned to Arm(s): WHO CVD Risk Assessment package | Intervention Type: BEHAVIORAL; Name: Health Insurance only; Assigned to Arm(s): Health Insurance only
C: Arm Label: Intervention; Type: OTHER; Interventions: Behavioral: Vascular Management Program, Behavioral: Clinical Care Coordinators, Behavioral: Web-based Vascular Tracker for Patient and Physician, Behavioral: Automated Telephone Reminder System | Intervention Type: BEHAVIORAL; Name: Vascular Management Program; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Clinical Care Coordinators; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Web-based Vascular Tracker for Patient and Physician; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Automated Telephone Reminder System; Assigned to Arm(s): Intervention
D: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis
Brief Summary: This is a phase III trial to determine whether adjunctive sertraline will lead to improved survival 18-week survival.

There was an initial phase I/II unmasked dose finding pharmacokinetic study of CSF concentrations in 172 persons conducted from August 2013 to August 2014. See NCT03002012.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, lamivudine and Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, lamivudine and Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, Lamivudine, Nevirapine; Assigned to Arm(s): 2
B: Arm Label: Earlier HIV Therapy; Type: EXPERIMENTAL; Interventions: Drug: efavirenz, Biological: nucleoside | Arm Label: Deferred HIV Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: efavirenz, Biological: nucleoside | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy | Intervention Type: BIOLOGICAL; Name: nucleoside; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy
C: Arm Label: Standard Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amphotericin B, Drug: Fluconazole | Arm Label: Fluconazole Low Dose; Type: EXPERIMENTAL; Interventions: Drug: Amphotericin B, Drug: Fluconazole | Arm Label: Fluconazole High Dose; Type: EXPERIMENTAL; Interventions: Drug: Amphotericin B, Drug: Fluconazole | Intervention Type: DRUG; Name: Amphotericin B; Assigned to Arm(s): Fluconazole High Dose, Fluconazole Low Dose, Standard Therapy | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): Fluconazole High Dose, Fluconazole Low Dose, Standard Therapy
D: Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Sertraline 400mg; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Sertraline 400mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Behavioural Treatment With Support on Communication and Information Technologies for the Management of Chronic Low Back Pain: A Randomized Clinical Trial
Brief Summary: The objective of this study is to investigate the short- and long-term efficacy of a Cognitive Behavioural Treatment program for chronic low back pain supported by information and communication technologies


Options:
A: Arm Label: DAHLIA treatment; Type: EXPERIMENTAL; Interventions: Behavioral: DAHLIA treatment | Arm Label: Treatment as usual; Type: OTHER; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: DAHLIA treatment; Assigned to Arm(s): DAHLIA treatment | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual
B: Arm Label: Mindfulness: Group A; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness meditation | Arm Label: Relaxation: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relaxation app | Arm Label: Treatment as usual: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness meditation; Assigned to Arm(s): Mindfulness: Group A | Intervention Type: BEHAVIORAL; Name: Relaxation app; Assigned to Arm(s): Relaxation: Group B
C: Arm Label: web page; Type: ACTIVE_COMPARATOR; Interventions: Other: Webpage | Arm Label: Webpage and situational feedback; Type: EXPERIMENTAL; Interventions: Other: Webpage and situation feedback | Intervention Type: OTHER; Name: Webpage; Assigned to Arm(s): web page | Intervention Type: OTHER; Name: Webpage and situation feedback; Assigned to Arm(s): Webpage and situational feedback
D: Arm Label: cognitive behaviour therapy supported by ICT; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation treatment and information, Behavioral: cognitive behavioural therapy (CBT), Behavioral: cognitive behaviour therapy supported by ICT | Arm Label: Rehabilitation treatment and information; Type: ACTIVE_COMPARATOR; Interventions: Other: Rehabilitation treatment and information | Arm Label: cognitive behavioural therapy (CBT); Type: EXPERIMENTAL; Interventions: Other: Rehabilitation treatment and information, Behavioral: cognitive behavioural therapy (CBT) | Intervention Type: OTHER; Name: Rehabilitation treatment and information; Assigned to Arm(s): Rehabilitation treatment and information, cognitive behaviour therapy supported by ICT, cognitive behavioural therapy (CBT) | Intervention Type: BEHAVIORAL; Name: cognitive behavioural therapy (CBT); Assigned to Arm(s): cognitive behaviour therapy supported by ICT, cognitive behavioural therapy (CBT) | Intervention Type: BEHAVIORAL; Name: cognitive behaviour therapy supported by ICT; Assigned to Arm(s): cognitive behaviour therapy supported by ICT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Soy Fiber Improves Weight Loss And Lipid Profile In Overweight And Obese Adults: A Randomized Controlled Trial
Brief Summary: The aim of this study is to examine the effects of soy fiber on body weight, body composition and blood lipids in overweight and obese participants.


Options:
A: Arm Label: Intensive Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Intensive | Arm Label: Routine Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Routine | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control (low saturated fat therapeutic diet) | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Intensive; Assigned to Arm(s): Intensive Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Routine; Assigned to Arm(s): Routine Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (low saturated fat therapeutic diet); Assigned to Arm(s): Control
B: Arm Label: Pulse Fibre; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Pulse fibre | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Control | Intervention Type: DIETARY_SUPPLEMENT; Name: Pulse fibre; Assigned to Arm(s): Pulse Fibre | Intervention Type: DIETARY_SUPPLEMENT; Name: Control; Assigned to Arm(s): Control
C: Arm Label: biscuits without soy fiber; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: biscuits supplemented with soy fiber | Arm Label: biscuits supplemented with soy fiber; Type: EXPERIMENTAL; Interventions: Dietary Supplement: biscuits supplemented with soy fiber | Intervention Type: DIETARY_SUPPLEMENT; Name: biscuits supplemented with soy fiber; Assigned to Arm(s): biscuits supplemented with soy fiber, biscuits without soy fiber
D: Arm Label: High Dose Chitin-Glucan; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Chitin-Glucan | Arm Label: Low Dose Chitin-Glucan; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Low Dose Chitin-Glucan | Arm Label: Low Dose Chitin-Glucan + Olive Extract; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low Dose Chitin-Glucan + Olive Extract | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Chitin-Glucan; Assigned to Arm(s): High Dose Chitin-Glucan | Intervention Type: DIETARY_SUPPLEMENT; Name: Low Dose Chitin-Glucan; Assigned to Arm(s): Low Dose Chitin-Glucan | Intervention Type: DIETARY_SUPPLEMENT; Name: Low Dose Chitin-Glucan + Olive Extract; Assigned to Arm(s): Low Dose Chitin-Glucan + Olive Extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration.


Options:
A: Arm Label: ACU-4429 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: ACU-4429 5 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: ACU-4429 10 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACU-4429; Assigned to Arm(s): ACU-4429 10 mg, ACU-4429 2.5 mg, ACU-4429 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Ozanimod1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Interferon β-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ozanimod placebo, Drug: Interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg | Intervention Type: DRUG; Name: Ozanimod placebo; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a placebo; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Efficacy of Methadone Versus Morphine for Treatment of Neonatal Abstinence Syndrome (NAS).
Brief Summary: Hypothesis is that the effectiveness of opiate treatment with morphine will result in shorter duration of opiate medication treatment and fewer infants treated with a second drug.


Options:
A: Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Clonidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clonidine | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): Clonidine
B: Arm Label: methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): methadone | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): morphine
C: Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine
D: Arm Label: Clonidine treatment; Type: EXPERIMENTAL; Interventions: Drug: Clonidine HCL | Intervention Type: DRUG; Name: Clonidine HCL; Assigned to Arm(s): Clonidine treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With the Combination of Sorafenib and Everolimus in Patients Affected by Relapsed and Non-resectable High-grade Osteosarcoma
Brief Summary: This is a trial for patients affected by metastatic or relapsed osteosarcoma which progressed after first or further line treatments. In this trial, all patients will be treated until progression or unacceptable toxicity with sorafenib and everolimus. The treatment with sorafenib and everolimus aimed to obtain a 50% rate of patients free from further progression of the disease after 6 months from study entry.


Options:
A: Arm Label: Part A, Group 1; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part A, Group 2; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 1; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 2; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Methotrexate | Arm Label: Part B, Group 3; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 4; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 50 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 5; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 25 mg, Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: CNTO 136 100 mg; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 2, Part B, Group 3 | Intervention Type: DRUG; Name: CNTO 136 50 mg; Assigned to Arm(s): Part B, Group 4 | Intervention Type: DRUG; Name: CNTO 136 25 mg; Assigned to Arm(s): Part B, Group 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 3, Part B, Group 4, Part B, Group 5 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 2, Part B, Group 3, Part B, Group 4, Part B, Group 5
B: Arm Label: single arm with Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm with Tremelimumab
C: Arm Label: Trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): Trabectedin | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
D: Arm Label: sorafenib and everolimus; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib, Drug: Everolimus | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): sorafenib and everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): sorafenib and everolimus

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Investigation of the Clinical Effectiveness of Adolescent Weight-management Delivered Via a Portable Device
Brief Summary: Though face-to-face treatment of childhood obesity can be effective, it is time consuming and costly. This study will test whether treatment can be delivered via an Android app and whether such treatment reduces obesity.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Device: Smartphone with APP, Behavioral: Counseling on lifestyles | Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Counseling on lifestyles | Intervention Type: DEVICE; Name: Smartphone with APP; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Counseling on lifestyles; Assigned to Arm(s): Intervention group, Lifestyle counseling
B: Arm Label: Control Group (CG); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Group (CG) | Arm Label: Intervention Group (IG); Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Group (IG) | Intervention Type: BEHAVIORAL; Name: Control Group (CG); Assigned to Arm(s): Control Group (CG) | Intervention Type: BEHAVIORAL; Name: Intervention Group (IG); Assigned to Arm(s): Intervention Group (IG)
C: Arm Label: W82GO; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: W82GO | Arm Label: Smartphone; Type: EXPERIMENTAL; Interventions: Device: smartphone application | Intervention Type: BEHAVIORAL; Name: W82GO; Assigned to Arm(s): W82GO | Intervention Type: DEVICE; Name: smartphone application; Assigned to Arm(s): Smartphone
D: Arm Label: Waiting Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Waiting Group | Arm Label: Conventional face to face PA & dietitian; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional face to face PA & dietitian | Arm Label: Digital Super Coach; Type: ACTIVE_COMPARATOR; Interventions: Other: Digital Super Coach | Arm Label: Digital Super Coach + minimal coaching; Type: ACTIVE_COMPARATOR; Interventions: Other: Digital Super Coach, Other: Digital Super Coach + minimal coaching | Intervention Type: OTHER; Name: Digital Super Coach; Assigned to Arm(s): Digital Super Coach, Digital Super Coach + minimal coaching | Intervention Type: OTHER; Name: Conventional face to face PA & dietitian; Assigned to Arm(s): Conventional face to face PA & dietitian | Intervention Type: OTHER; Name: Digital Super Coach + minimal coaching; Assigned to Arm(s): Digital Super Coach + minimal coaching | Intervention Type: OTHER; Name: Waiting Group; Assigned to Arm(s): Waiting Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Investigation of the Clinical Effectiveness of Adolescent Weight-management Delivered Via a Portable Device
Brief Summary: Though face-to-face treatment of childhood obesity can be effective, it is time consuming and costly. This study will test whether treatment can be delivered via an Android app and whether such treatment reduces obesity.


Options:
A: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention - Web; Type: EXPERIMENTAL; Interventions: Behavioral: Weekly access to interactive web site | Arm Label: Intervention - Group; Type: EXPERIMENTAL; Interventions: Behavioral: Group | Arm Label: Intervention - Cell Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Cell Phone | Intervention Type: BEHAVIORAL; Name: Cell Phone; Assigned to Arm(s): Intervention - Cell Phone | Intervention Type: BEHAVIORAL; Name: Weekly access to interactive web site; Assigned to Arm(s): Intervention - Web | Intervention Type: BEHAVIORAL; Name: Group; Assigned to Arm(s): Intervention - Group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sugar-sweetened beverage consumption | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sugar-sweetened beverage consumption; Assigned to Arm(s): 1
C: Intervention Type: BEHAVIORAL; Name: Internet-based intervention designed to reduce binge eating and improve healthy weight regulation; Assigned to Arm(s): N/A
D: Arm Label: W82GO; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: W82GO | Arm Label: Smartphone; Type: EXPERIMENTAL; Interventions: Device: smartphone application | Intervention Type: BEHAVIORAL; Name: W82GO; Assigned to Arm(s): W82GO | Intervention Type: DEVICE; Name: smartphone application; Assigned to Arm(s): Smartphone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin in Antiretroviral Naive Patients Co-infected With HIV and Tuberculosis in India.
Brief Summary: The purpose of the study is to evaluate the efficacy and safety of Nevarapine and Rifampicin vs Efavirenz and Rifampicin in antiretroviral naive patients co-infected with HIV and TB and to investigate whether Rifampicin co-administration in clinical practice leads to a clinically relevant decrease of Nevirapine plasma concentrations in Indian patients co-infected with HIV and Tuberculosis and to characterize drug-associated toxicities (especially hepatic).


Options:
A: Arm Label: Intervention 2: Nevirapine; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: Intervention 2: Efavirenz; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Intervention 2: Nevirapine | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): Intervention 2: Efavirenz
B: Arm Label: Efavirenz; Type: EXPERIMENTAL; Interventions: Drug: efavirenz | Arm Label: Nevirapine; Type: EXPERIMENTAL; Interventions: Drug: nevirapine | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Efavirenz | Intervention Type: DRUG; Name: nevirapine; Assigned to Arm(s): Nevirapine
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Didanosine, Lamivudine, Nevirapine | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Didanosine, Lamivudine, Efavirenz | Intervention Type: DRUG; Name: Didanosine, Lamivudine, Efavirenz; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Didanosine, Lamivudine, Nevirapine; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine based therapy, Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz based therapy, Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) | Intervention Type: DRUG; Name: Nevirapine based therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Efavirenz based therapy; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z); Assigned to Arm(s): 1, 2

Answer: A